Osteoarthritis (OA) is one of the age‐related diseases and is highly present on the knees. Obesity and mechanical injuries as a risk factor of OA are attributed to cartilage disintegration, joint loading, and inflammation. This study is aimed at investigating the effects of seahorse protein hydrolysate (SH) on posttraumatic osteoarthritis in an obesity rat. The OA model was developed by anterior cruciate ligament transection with medial meniscectomy in a high‐fat diet‐ (HFD‐) induced obesity rat model. The male Sprague‐Dawley rats were fed a HFD for 6 weeks before OA surgery. The OA rats were treated with oral gavage by 4, 8, or 20 mg/kg of body weight of SH for 6 weeks of treatment. The expressions of plasma proinflammatory factors, C‐telopeptide of type II collagen, and matrix metalloproteinase‐ (MMP‐) 3 and MMP‐13 were reduced by SH treatment. Plasma superoxide dismutase and glutathione peroxidase activities were enhanced by SH. SH also relieved the pain of the knee joint and swelling as well as decreased proteoglycan loss in the knee articular cartilage caused by osteoarthritis. Based on these results, SH suppressed proinflammatory factors and attenuated cartilage degradation and pain in the OA model. Therefore, seahorse protein hydrolysate might be a potential opportunity for improving the development of osteoarthritis.
Background: Delayed and failed fracture repair and bone healing remain significant public health issues. Dietary supplements serve as a safe, inexpensive, and non-surgical means to aid in different stages of fracture repair. Studies have shown that amorphous calcium carbonate (ACC) is absorbed 2 to 4.6 times more than crystalline calcium carbonate in humans. Objectives: In the present study, we assessed the efficacy of ACC on femoral fracture healing in a male Wistar rat model. Methods: Eighty male Wistar rats were randomly divided into five groups (n = six per group): sham, fracture + water, fracture + 0.5× (206 mg/kg) ACC, fracture + 1× ACC (412 mg/kg), and fracture + 1.5× (618 mg/kg) ACC, where ACC refers to the equivalent supplemental dose of ACC for humans. A 21-gauge needle was placed in the left femoral shaft, and we then waited for three weeks. After three weeks, the sham group of rats was left without fractures, while the remaining animals had their left mid-femur fractured with an impactor, followed by treatment with different doses of oral ACC for three weeks. Weight-bearing capacity, microcomputed tomography, and serum biomarkers were evaluated weekly. After three weeks, the rats were sacrificed, and their femur bones were isolated to conduct an evaluation of biomechanical strength and histological analysis. Results: Weight-bearing tests showed that treatment with ACC at all the tested doses led to a significant increase in weight-bearing capacity compared to the controls. In addition, microcomputed tomography and histological studies revealed that ACC treatment improved callus formation dose-dependently. Moreover, biomechanical strength was improved in a dose-dependent fashion in ACC-treated rats compared to the controls. In addition, supplementation with ACC significantly lowered bone formation and resorption marker levels two–three weeks post-fracture induction, indicating accelerated fracture recovery. Conclusions: Our preliminary data demonstrate that ACC supplementation improves fracture healing, with ACC-supplemented rats healing in a shorter time than control rats.
Objectives: This study aimed to investigate the effect of amorphous calcium carbonate (ACC) supplementation on bone growth in growing rats. Methods: We used 3-week-old male Wistar rats to simulate childhood and adolescent growth stages. Rats were divided into four groups as follows: a control group (C), a low-dose group (L, 20.65 mg/kg body weight (BW) ACC), a medium-dose group (M, 206.5 mg/kg BW ACC), and a high-dose group (H, 413 mg/kg BW ACC) administered by gavage. Body length (BL) and BW were measured weekly. The bone mineral density (BMD) of two lumbar vertebrae (L3 and L4) and the left femur were analyzed by micro-computed tomography (μCT) at 0, 4, 8, and 12 weeks. At the end of 12 weeks, the rats were sacrificed. After that, blood samples were collected from the abdominal aorta. Femurs and tibias were collected and weighed, and their lengths were measured. Then, bone samples were used to perform histopathological and histomorphometric analyses. Results: It showed that ACC supplementation in growing rats increased the trabecular bone thickness and serum bone formation biomarkers. Furthermore, high-dose ACC decreased serum bone resorption biomarkers and increased BMD. Conclusions: ACC supplementation can enhance osteoblast metabolism and inhibit osteoclast metabolism, resulting in a higher bone formation rate compared to bone resorption. This led to increased trabecular bone thickness, a higher BMD, and supported bone growth.
Rheumatoid arthritis (RA) is associated with increased risks of osteoporosis and fracture. Amorphous calcium carbonate (ACC) may enhance osteogenic differentiation and increase bone mineral density (BMD). The effects of ACC supplementation on BMD and bone turnover markers (BTMs) in RA have not been explored. This study investigated the influence of ACC supplementation on BMD, BTMs, and the risk of osteoporotic fractures in RA patients. We enrolled 67 RA patients with osteopenia or osteoporosis. BMD was measured by dual-energy X-ray absorptiometry before and after 1 year of ACC supplementation, providing elemental calcium 800 mg/day combined with vitamin D3 400 IU/day. Serum levels of N-terminal propeptide of type I collagen and C-terminal cross-linking telopeptide were measured at baseline and every 3 months following ACC supplementation. The 10-year fracture probability was calculated using the Fracture Risk Assessment Tool (FRAX®), and RA activity was assessed using the 28-joint disease activity score. Multivariate regression analysis revealed that age and corticosteroid dosage ≥5 mg were significant risk factors for major osteoporotic fracture. The 28-joint disease activity scores were inversely correlated with BMD of the right femoral neck ( r = −0.426, P < .001) and left femoral neck ( r = −0.383, P < .005). After 12 months of ACC supplementation, bilateral femoral neck BMD increased significantly (from 0.61 to 0.63 g/cm 2 , both P < .001), accompanied by improvement in T-scores. Serum levels of N-terminal propeptide of type I collagen and C-terminal cross-linking telopeptide were significantly decreased (mean 53.42 vs 41.24 ng/mL, P < .001; 0.29 vs 0.25 ng/mL, P < .05, respectively). Twelve-month ACC supplementation increased bilateral femoral neck BMD and reduced BTM levels in RA patients, particularly in anti-citrullinated peptide antibody–positive patients.
Delayed and failed fracture repair and bone healing remains a significant public health issue. Dietary supplements serve as a safe, inexpensive, and non-surgical means to aid in different stages of fracture repair. Studies have shown that amorphous calcium carbonate (ACC) is absorbed 2 to 4.6 times higher than crystalline calcium carbonate in humans. In the present study, we assessed the efficacy of Density ACC supplement on femoral fracture healing in a male Wistar rat model. Fifty male Wistar rats were divided into five groups (n = 6 per group); Sham, Fracture + Water, Fracture + 0.5x (206 mg/kg) ACC, Fracture + 1x ACC (412 mg/kg) and Fracture + 1.5x (618 mg/kg) ACC to that of human supplement doses of ACC. A 21-gauze needle was placed in the left femoral shaft and waited three weeks. After three weeks, the sham group of rats was left without fracture, and the remaining animals were fractured with an impactor at the left mid-femur, followed by treatment with different doses of ACC for three weeks orally. Weight-bearing, microcomputed tomography, and serum biomarkers were evaluated weekly. After three weeks, the rats were sacrificed and femur bones were isolated for the evaluation of biomechanical strength and histological analysis. Weight-bearing test showed that treatment with ACC at all the tested doses led to a significant increase in weight-bearing compared to the controls. In addition, microcomputed- tomography and histological studies revealed that ACC treatment improved callus formation dose-dependently. Moreover, biomechanical strength was better in ACC-treated rats in a dose-dependent fashion than in the controls. In addition, supplementation with ACC significantly lowered the bone formation and resorption (BFR) marker levels 2-3 weeks post-fracture induction indicating accelerated fracture recovery. Our preliminary data demonstrate that ACC supplement improves fracture healing in a shorter time than the control rats.